PDCD1 and non-small cell lung carcinoma: It has been reported that adding anti-angiogenic therapy to cranial radiotherapy and PD-1 inhibitors significantly improves intracranial local and distant progression-free survival in driver gene-negative NSCLC patients with brain metastases, with manageable toxicity (34).